Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
With biosimilar monoclonal antibodies now entering the market and a surge of biosimilars expected once the patents for major pioneer products expire, this article analyses experiences so far and future market dynamics.
This article analyses the characteristics of the pipeline for experimental drugs for central nervous system disorders and how they have fared in the clinical phases prior to FDA approval over the past two decades.
This analysis provides an overview of the current pipeline of drugs for psoriasis and an outlook for the psoriasis market, which is growing substantially.
A number of potentially disease-modifying therapies are in late-stage clinical trials for Alzheimer disease (AD). This article discusses the different types of drugs in the AD drug pipeline and provides an outlook of their market potential.
This article analyses the first three years of the US Food and Drug Administration's breakthrough therapy designation programme, which was established to expedite development and approval of products to treat serious diseases.
This article discusses the opportunities and challenges in the application of financially adaptive clinical trials, which combine key aspects of adaptive trial design and financial analytics.
Using a novel metric that links investment in drug research and development (R&D) to output in terms of revenue from the resultant drugs, this article analyses trends in R&D productivity overall and in specific therapeutic areas, and discusses strategies for improvement.
The market for drugs to treat chronic lymphocytic leukaemia has changed substantially recently with the introduction of novel targeted therapies. This article discusses the treatment landscape and highlights agents in the late-stage pipeline.
This analysis of changes in the length of clinical trials over time provides evidence of increased efficiency in drug development and investigates the possible contributing factors.
Several new drugs have recently been approved for the treatment of breast cancer, and this analysis provides a market outlook as well as an insight into the pipeline of agents in late-stage development.
Several breakthrough drugs have recently been approved to treat hepatitis C virus (HCV) infection. To understand what it takes to achieve such success, Calcoen and colleagues analysed attrition rates for HCV drug projects over the last 20 years compared with other indications.
